Venmax Drugs And Pharmaceuticals Ltd. (VENMA) Share Price Surges 8.5% Today

Venmax Drugs And Pharmaceuticals Ltd. Share Price surged 8.5% today, reaching Rs 17.49. The company, with a market cap of Rs 18.67 crore, is a micro-cap stock.

Venmax Drugs And Pharmaceuticals Ltd. Share Price experienced a notable surge of 8.5% today, closing at Rs 17.49. This significant price movement places the company in the spotlight within the micro-cap category, where it successfully surpassed the qualifying threshold of 8.1%. With a market capitalisation of Rs 18.67 crore, Venmax Drugs And Pharmaceuticals Ltd. has captured investor attention, marking its presence in the healthcare sector, specifically within the pharmaceuticals and drugs industry.

The stock opened at Rs 16.5, reaching a high of Rs 17.49 and a low of Rs 15.85 during the trading session. The total volume traded on the BSE was 10,520 shares, with a turnover of Rs 0.02 crore. This surge in share price highlights the company's position as a top gainer in today's market, drawing interest from investors and analysts alike.

Venmax Drugs And Pharmaceuticals Ltd. Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 17.49
Previous Close	Rs 16.12
Today's Change	+Rs 1.37 (+8.5%)
Day Open	Rs 16.5
Day High	Rs 17.49
Day Low	Rs 15.85
Current Volume (BSE)	10,520
BSE Traded Volume	10,520
Combined NSE + BSE Volume	10,520
Turnover	Rs 0.02 crore
Market Capitalisation	Rs 18.67 crore
Market Cap Category	Micro Cap
Qualifying Threshold Cleared	8.1%

Today's trading session saw Venmax Drugs And Pharmaceuticals Ltd. Share Price rise by 8.5%, closing at Rs 17.49. The previous close was Rs 16.12, indicating a day change of Rs 1.37. The stock opened at Rs 16.5, with a day high of Rs 17.49 and a day low of Rs 15.85. The total turnover for the day was Rs 0.02 crore, with a volume of 10,520 shares traded on the BSE.

As a micro-cap stock, Venmax Drugs And Pharmaceuticals Ltd. had to clear a qualifying threshold of 8.1% to be considered a significant price mover today. The company's market capitalisation stands at Rs 18.67 crore, reflecting its position within the micro-cap category. This price action has positioned Venmax Drugs And Pharmaceuticals Ltd. as a top gainer, attracting attention from market participants.

The stock's performance today is noteworthy, given its ability to surpass the qualifying threshold and achieve a substantial gain. This development has sparked interest in the company's future prospects, as investors and analysts evaluate its potential within the healthcare sector.

Venmax Drugs And Pharmaceuticals Ltd. Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 18.67 crore
P/E Ratio	75.59x
P/B Ratio	1.32x
ROE	0%
ROCE	0%
EPS	Rs 0.21
Book Value Per Share	Rs 12.19
Dividend Yield	0%

Venmax Drugs And Pharmaceuticals Ltd. was valued at a P/E ratio of 75.59x, a P/B ratio of 1.32x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 0% and ROCE of 0%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 0.21, book value per share of Rs 12.19, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Venmax Drugs And Pharmaceuticals Ltd. has a market capitalisation of Rs 18.67 crore, positioning it within the micro-cap category. The company's P/E ratio stands at 75.59, significantly higher than the industry median of 18.4, indicating a potentially expensive valuation relative to its peers. The P/B ratio is 1.32, below the industry median of 1.84, suggesting a more reasonable valuation in terms of book value.

The company's EPS is Rs 0.21, reflecting the earnings attributable to each share. The book value per share is Rs 12.19, indicating the accounting net worth behind each share. Venmax Drugs And Pharmaceuticals Ltd. does not offer a dividend yield, which may impact income-focused investors.

With an ROE and ROCE of 0, the company currently shows no return on equity or capital employed, which may raise concerns about its profitability and efficiency. These fundamental metrics provide a mixed picture, highlighting the need for investors to consider both valuation and financial performance when assessing the company's potential.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Companies in Benchmark	137
Company P/E Ratio	75.59x
Benchmark Median P/E	18.4x
Benchmark Average P/E	58.17x
Benchmark P/E Range	0x to 3,482.29x
Companies with P/E Data	137
Company P/B Ratio	1.32x
Benchmark Median P/B	1.84x
Company ROE	0%
Benchmark Median ROE	9.93%
Company ROCE	0%
Benchmark Median ROCE	12.97%
Company Market Capitalisation	Rs 18.67 crore
Benchmark Median Market Cap	Rs 151.87 crore

Venmax Drugs And Pharmaceuticals Ltd. (VENMA) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs. The numerical benchmark uses 137 same industry companies from the supplied master-data set.

Venmax Drugs And Pharmaceuticals Ltd. (VENMA) has a P/E ratio of 75.59x, which is above the benchmark median of 18.4x, a difference of +310.82%. The benchmark contains 137 companies with P/E data, ranging from 0x to 3,482.29x. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Venmax Drugs And Pharmaceuticals Ltd. (VENMA) has a ROE of 0%, which is below the benchmark median of 9.93%, a difference of -100%. Venmax Drugs And Pharmaceuticals Ltd. (VENMA) has a ROCE of 0%, which is below the benchmark median of 12.97%, a difference of -100%.

Track today's top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

Venmax Drugs And Pharmaceuticals Ltd. operates within the healthcare sector, specifically in the pharmaceuticals and drugs industry. The industry comprises 137 companies, with a median P/E of 18.4 and an average P/E of 58.17. Venmax's P/E ratio of 75.59 is significantly above the industry median, suggesting a higher valuation compared to its peers.

The company's P/B ratio of 1.32 is below the industry median of 1.84, indicating a potentially undervalued position in terms of book value. However, with an ROE and ROCE of 0, Venmax falls short of the industry median ROE of 9.93 and ROCE of 12.97, highlighting challenges in profitability and capital efficiency.

The healthcare sector, with 198 companies, presents a diverse landscape, and Venmax Drugs And Pharmaceuticals Ltd.'s market capitalisation of Rs 18.67 crore places it below the industry median of Rs 151.87 crore. This context underscores the importance of evaluating the company's position within the sector and its potential for growth and improvement.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Desh Rakshak Aushdhalaya Ltd.	DESHRAK	17.66	31.38	1.62	5.05	6.69
Zenith Health Care Ltd.	ZENITHHE	17.41	3,482.29	2.35	6.64	8.56
Colinz Laboratories Ltd.	COLINZ	20.8	40.55	2.07	2.94	4.28
Omkar Pharmachem Ltd.	OMKARPH	16.44	135.85	0.45	2.59	0.22
Ishita Drugs & Industries Ltd.	ISHITADR	22.15	28.5	1.91	11.25	14.39

Venmax Drugs And Pharmaceuticals Ltd. (VENMA) has a P/E ratio of 75.59x compared with the displayed peer median of 40.55x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 0% compares with a peer median of 5.05% across the companies shown in the table. ROCE stood at 0% versus the displayed peer median of 6.69%, providing a capital-efficiency comparison. Venmax Drugs And Pharmaceuticals Ltd. (VENMA) has a market capitalisation of Rs 18.67 crore. Among the 5 peers shown, 2 have a larger market capitalisation.

In comparison to its peers, Venmax Drugs And Pharmaceuticals Ltd. has a market capitalisation of Rs 18.67 crore, placing it in the micro-cap category. Desh Rakshak Aushdhalaya Ltd. has a market cap of Rs 17.66 crore, with a P/E of 31.38, indicating a lower valuation compared to Venmax. Zenith Health Care Ltd., with a market cap of Rs 17.41 crore, has an exceptionally high P/E of 3482.29, reflecting a unique valuation scenario.

Colinz Laboratories Ltd. and Omkar Pharmachem Ltd. have market caps of Rs 20.8 crore and Rs 16.44 crore, respectively, with P/E ratios of 40.55 and 135.85. Ishita Drugs & Industries Ltd. has a market cap of Rs 22.15 crore and a P/E of 28.5, showcasing a more moderate valuation.

Venmax's P/E ratio of 75.59 is higher than most peers, indicating a potentially expensive valuation. The company's ROE and ROCE of 0 contrast with peers like Ishita Drugs & Industries Ltd., which has an ROE of 11.25 and ROCE of 14.39, highlighting areas for potential improvement.

Why Investors Are Watching Venmax Drugs And Pharmaceuticals Ltd.

Investors are closely monitoring Venmax Drugs And Pharmaceuticals Ltd. due to its recent price surge and position within the micro-cap category. The company's valuation, technical position, and sector context are key areas of interest.

• Price Action: 8.5% rise today, closing at Rs 17.49.
• Technical Position: RSI at 47.44, indicating neutral momentum.
• Fundamental Context: P/E of 75.59, higher than industry median.
• Sector Positioning: Operates in the healthcare sector, pharmaceuticals industry.

Investors should continue to monitor Venmax Drugs And Pharmaceuticals Ltd.'s financial performance, market trends, and sector developments to assess its potential for future growth and investment opportunities.

About Venmax Drugs And Pharmaceuticals Ltd.

Venmax Drugs And Pharmaceuticals Ltd. is a company operating in the healthcare sector, specifically within the pharmaceuticals and drugs industry. The company focuses on the development, manufacturing, and distribution of pharmaceutical products, catering to various therapeutic segments.

With a market capitalisation of Rs 18.67 crore, Venmax Drugs And Pharmaceuticals Ltd. is classified as a micro-cap stock. The company's operations are primarily based in India, and it aims to provide quality pharmaceutical solutions to meet the healthcare needs of the population.

Venmax Drugs And Pharmaceuticals Ltd. continues to explore opportunities for growth and expansion within the competitive pharmaceutical landscape, leveraging its expertise and industry knowledge to enhance its market presence.

Track Venmax Drugs And Pharmaceuticals Ltd. Share Price on Univest

Use Venmax Drugs And Pharmaceuticals Ltd. (VENMA) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Investors and market enthusiasts can track Venmax Drugs And Pharmaceuticals Ltd. Share Price on Univest. The platform provides live updates on share price, technical indicators, fundamental ratios, and shareholding patterns. Users can also access insights into 52-week levels and market trends, enabling informed decision-making.

Frequently Asked Questions

What is the current share price of Venmax Drugs And Pharmaceuticals Ltd.?

Ans. The current share price of Venmax Drugs And Pharmaceuticals Ltd. is Rs 17.49, reflecting an 8.5% increase from the previous close of Rs 16.12. The stock moved 8.5% during the session.

Why did Venmax Drugs And Pharmaceuticals Ltd. share price rise today?

Ans. Venmax Drugs And Pharmaceuticals Ltd. share price rose by 8.5% today, surpassing the micro-cap qualifying threshold of 8.1%, with no specific catalyst identified. The stock moved 8.5% during the session.

What is the market capitalisation of Venmax Drugs And Pharmaceuticals Ltd.?

Ans. The market capitalisation of Venmax Drugs And Pharmaceuticals Ltd. is Rs 18.67 crore, categorising it as a micro-cap stock within the healthcare sector. The company operates in the Healthcare sector.

How does Venmax Drugs And Pharmaceuticals Ltd.'s P/E ratio compare to the industry?

Ans. Venmax Drugs And Pharmaceuticals Ltd.'s P/E ratio of 75.59 is significantly higher than the industry median of 18.4, indicating a potentially expensive valuation. The company trades at a P/E ratio of 75.59x.

How does Venmax Drugs And Pharmaceuticals Ltd.'s ROE compare to the industry?

Ans. Venmax Drugs And Pharmaceuticals Ltd.'s ROE of 0 is below the industry median of 9.93, highlighting challenges in profitability. ROE stands at 0%. ROCE stands at 0%. The relevant peer median ROE is 9.93%.

What is the sector of Venmax Drugs And Pharmaceuticals Ltd.?

Ans. Venmax Drugs And Pharmaceuticals Ltd. operates in the healthcare sector, specifically within the pharmaceuticals and drugs industry. The stock belongs to the Healthcare sector. Its industry classification is Pharmaceuticals & Drugs.

How does Venmax Drugs And Pharmaceuticals Ltd.'s market cap compare to its peers?

Ans. Venmax Drugs And Pharmaceuticals Ltd.'s market cap of Rs 18.67 crore places it in the micro-cap category, comparable to peers like Desh Rakshak Aushdhalaya Ltd. The company operates in the Healthcare sector.